NASDAQ$MIST
Milestone Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Milestone Pharmaceuticals reported third quarter 2021 financial results and provided a clinical and corporate update.
Milestone Pharmaceuticals reported their third quarter financial results, highlighting the progress of the etripamil PSVT program and the advancement of Phase 3 efficacy and safety studies. They also completed patient research to understand the burden experienced by patients. Data from an analysis of heart rate in patients treated in the NODE-301 trial will be presented at the AHA Scientific Sessions 2021 meeting.
- Continued progress across etripamil PSVT program.
- Advanced Phase 3 efficacy and safety studies.
- Completed important patient research for deeper understanding of patient burden.
- Data from NODE-301 trial will be presented at AHA Scientific Sessions 2021.
Headline financials
Revenue & EPS history
Milestone Pharmaceuticals · Revenue · Quarterly
$238K
Forward guidance
The press release contains forward-looking statements regarding the potential of etripamil, the design, progress, timing, scope and results of the RAPID and ReVeRA trials, Milestone’s ability to execute on the remainder of the PSVT program, Milestone’s ongoing plans to study etripamil in atrial fibrillation patients, the sufficiency of Milestone’s current cash resources to support its operations, and estimates about the addressable market and commercial potential for treatments of atrial fibrillation with rapid ventricular rate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q3 2021
+2.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.5%
Avg return
30 days after
67%
18 / 27 earnings
Positive
+24.1%
Q3 2021
Best reaction
-23.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | — | — | — | |
| Q1 2026 | -9.5% | -23.2% | — | |
| Q3 2025 | +1.0% | +21.5% | +26.2% | |
| Q2 2025 | +7.1% | +9.7% | +23.2% | |
| Q1 2025 | -1.7% | +8.4% | +38.7% | |
| Q4 2024 | +7.9% | -53.7% | -38.9% | |
| Q3 2024 | -5.2% | -12.4% | -4.1% | |
| Q1 2024 | +1.2% | +2.4% | -16.5% | |
| Q4 2023 | +16.0% | +20.7% | +9.3% | |
| Q3 2023 | -23.0% | -24.4% | -13.7% | |
| Q2 2023 | +1.6% | +2.6% | -7.1% | |
| Q1 2023 | +12.8% | +0.5% | +1.3% | |
| Q4 2022 | -4.0% | -0.3% | -9.0% | |
| Q3 2022 | +13.0% | +7.1% | -0.7% | |
| Q2 2022 | +3.6% | +5.3% | +29.2% | |
| Q1 2022 | -2.5% | +1.6% | +1.6% | |
| Q4 2021 | +12.4% | +17.5% | +22.0% | |
| Q3 2021 | +24.1% | +13.9% | +4.5% | |
| Q2 2021 | +0.2% | +2.1% | +7.1% | |
| Q1 2021 | +0.5% | +2.9% | +8.1% | |
| Q4 2020 | -6.6% | -2.4% | -4.2% | |
| Q3 2020 | +6.1% | +6.0% | +19.8% | |
| Q2 2020 | -1.8% | +0.3% | -12.2% | |
| Q1 2020 | +0.3% | +4.8% | +29.5% | |
| Q4 2019 | +7.4% | +8.7% | -90.4% | |
| Q3 2019 | -4.2% | -1.2% | -7.2% | |
| Q2 2019 | +7.8% | +9.9% | +38.1% | |
| Q1 2019 | +3.4% | -4.5% | -16.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro